Post-traumatic Stress Disorder Clinical Trials Pipeline Analysis: 25+ Companies are Working to Improve the Treatment Space | DelveInsight
DelveInsight’s post-traumatic stress disorder pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for post-traumatic stress disorder treatment.
New York, USA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- *Post-traumatic Stress Disorder Clinical Trials Pipeline Analysis: 25+ Companies are Working to Improve the Treatment Space | DelveInsight*
*DelveInsight’s post-traumatic stress disorder pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for post-traumatic stress disorder treatment. *
DelveInsight’s *'**Post-traumatic Stress Disorder Pipeline Insight – 2022**'* report provides comprehensive global coverage of available, marketed, and pipeline PTSD therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the post-traumatic stress disorder pipeline domain.
*Key Takeaways from the Post-traumatic Stress Disorder Pipeline Report*
· DelveInsight’s post-traumatic stress disorder pipeline report depicts a robust space with* 25+ *active players working to develop *25+ *pipeline therapies for post-traumatic stress disorder treatment.
· Key post-traumatic stress disorder companies such as *Aptinyx, Nobilis Therapeutics Inc., Jazz Pharmaceuticals, COMPASS Pathways, Bionomics Limited, Boehringer Ingelheim, Otsuka Pharmaceutical Development & Commercialization, Inc., Halucenex Life Sciences, Bionorica SE, MAPS Europe B.V., Hoffmann-La Roche, Praxis Precision Medicines, Alto Neuroscience, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Psy Therapeutics Inc, Chronos Therapeutics, Mydecine Innovations Group, ATAI LIFE SCIENCES N.V., Acer Therapeutics, Alzamend Neuro, Inc., Innovation1 Biotech Inc., Lophora, Virpax Pharmaceuticals, Alto Neuroscience, VistaGen, ANANDA Scientific, Bright Minds Biosciences, *and others are evaluating novel post-traumatic stress disorder drug candidates to improve the treatment landscape.
· Promising post-traumatic stress disorder pipeline therapies in various stages of development include *NYX-783, NBTX-001, JZP150, Psilocybin, BNC210, BI 1358894, Brexpiprazole, BX-1, MDMA, Balovaptan, PRAX-114, ALTO-100, Lu AG06466, TNX-102, PSY-05, TrkB Modulator, MYCO-001, EMP-01 / MDMA derivative, ACER-801, AL001, Psilocin Prodrug, PES200, ALTO-100, ALTO-202, Liquid Structure™ Cannabidiol (CBD), *and others.
· In October 2022,* Acer Therapeutics Inc.* announced the expansion of *ACER-801 (osanetant)* into a new indication for the reduction of the frequency and severity of acute stress disorder and post-traumatic stress disorder (PTSD).
· In September 2022, *atai Life Sciences N.V., *which is developing *EMP-01*, a 3,4-methylenedioxy-methamphetamine (MDMA) derivative for the treatment of post-traumatic stress disorder (PTSD) and other indications, announced it's Phase 1 study has received regulatory and ethics approvals required from Medsafe and HDEC, respectively, to initiate participant enrollment.
· In May 2022, data from preclinical studies of *Aptinyx’s NYX-783* in models of post-traumatic stress disorder (PTSD) were presented in a poster at the American Psychiatric Association Annual Meeting which was held from May 21 – 25, 2022, in New Orleans, LA.
· In May 2022, *Beckley Psytech Limited* and *Lophora ApS* announced the companies had entered into a research and development collaboration. Under the terms of the agreement, Beckley Psytech will jointly fund continuing development of the Lophora pipeline and collaborate broadly on R&D.
· In May 2022, *The University of Nebraska Medical Center (UNMC) *and *ANANDA Scientific Inc *announced a collaboration in a new clinical trial investigating treatment for adults with Post-Traumatic Stress Disorder (PTSD). The study will evaluate the effectiveness of *Nantheia™ ATL5*, an investigational drug using cannabidiol in ANANDA’s proprietary delivery technology. An investigational new drug (IND) application for the trial has been approved by the U.S. Food and Drug Administration (FDA).
· In February 2022, *Novamind Inc.* announced that it is enrolling participants in phase II clinical trial sponsored by *Alto Neuroscience.* The eight-week clinical trial currently underway at Novamind's Draper, Utah research site is investigating an antidepressant medication for adults with major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) (the "Alto Clinical Trial").
· In December 2021, *Jazz Pharmaceuticals plc* announced that the first patient had been enrolled in Phase 2 clinical trial evaluating the safety and efficacy of *JZP150*, an investigational first-in-class small molecule for the treatment of adults with post-traumatic stress disorder (PTSD). JZP150 is a highly selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), designed to address the underlying cause of PTSD (impairment of fear extinction and its consolidation), as well as patients' associated symptoms (anxiety, insomnia, and nightmares).
Request a sample and discover the recent advances in post-traumatic stress disorder treatment drugs @*Post-traumatic Stress Disorder Pipeline Report*
The post-traumatic stress disorder pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage post-traumatic stress disorder products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the post-traumatic stress disorder pipeline landscape.
*Post-traumatic Stress Disorder Overview*
Post-traumatic stress disorder (PTSD) is defined as "the complicated physical, cognitive, emotional, and behavioral consequences of psychological trauma." It is distinguished by intrusive thoughts, nightmares, flashbacks to previous traumatic events, avoidance of traumatic reminders, hypervigilance, and sleep disruption, all of which contribute to significant social, occupational, and interpersonal dysfunction. Post-traumatic stress disorder causes include intense fear, helplessness, and horror.
Symptoms of PTSD can appear as soon as a month after a stressful event, but they can also appear years later. These post-traumatic stress disorder symptoms cause significant problems in social and work situations and relationships. They can also impair one's ability to perform routine daily tasks. There are four types of post-traumatic stress disorder symptoms: intrusive recollections, avoidance, unfavorable changes in thinking and mood, and changes in physical and emotional reactions. Symptoms can vary over time and between individuals.
For post-traumatic stress disorder diagnosis, the doctor will most likely perform a physical exam to rule out any medical issues that may be causing the symptoms - a psychological evaluation that includes a discussion of the signs and symptoms, as well as the event or events that precipitated them - and will employ criteria from the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).
Find out more about therapy for post-traumatic stress disorder @*Post-traumatic Stress Disorder Treatment Drugs*
*A snapshot of the Post-traumatic Stress Disorder Pipeline Drugs mentioned in the report:*
*Drugs* *Company* *Phase * *MoA* *RoA*
Brexpiprazole Otsuka Pharmaceutical Development & Commercialization Phase III Dopamine D2 receptor partial agonist Oral
NBTX-001 Nobilis Therapeutics Phase II/III NMDA receptor antagonist Inhalation
BNC 210 Bionomics Phase II Alpha7 nicotinic acetylcholine receptor antagonist Oral
BI 1358894 Boehringer Ingelheim Phase II TRPC4 cation channel inhibitor Oral
BX-1 Bionorica SE Phase II Cannabinoid receptor CB1 and CB2 agonist Oral
Lu AG06466 H. Lundbeck A/S Phase I Monoacylglycerol lipase inhibitor Oral
Learn more about the emerging drugs to treat post-traumatic stress disorder @*PTSD Clinical Trials*
*Post-traumatic Stress Disorder Therapeutics Assessment*
The *post-traumatic stress disorder pipeline* report proffers an integral view of the post-traumatic stress disorder emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
*Scope of the Post-traumatic Stress Disorder Pipeline Report *
· *Coverage*: Global
· *Therapeutic Assessment By Product Type: *Mono, Combination, Mono/Combination
· *Therapeutic Assessment By Clinical Stages: *Discovery, Pre-clinical, Phase I, Phase II, Phase III
· *Therapeutics Assessment* *By Route of Administration:* Inhalation, Intranasal, Intravenous, Parenteral, Subcutaneous, Oral
· *Therapeutics Assessment* *By Molecule Type*: Antibody, Antisense oligonucleotides, Immunotherapy, Monoclonal antibody, Peptides, Protein, Recombinant protein, Small molecule, Stem Cell, Vaccine
· *Therapeutics Assessment* *By Mechanism of Action: *Dopamine D2 receptor partial agonists, Serotonin 1A receptor partial agonists, Serotonin 2A receptor antagonists, NMDA receptor antagonists, Alpha7 nicotinic acetylcholine receptor antagonists, Monoacylglycerol lipase inhibitors, TRPC4 cation channel inhibitors, TRPC5 cation channel inhibitors, Cannabinoid receptor CB1 agonists, Cannabinoid receptor CB2 agonists
· *Key Post-traumatic Stress Disorder Companies*: Aptinyx, Nobilis Therapeutics Inc., Jazz Pharmaceuticals, COMPASS Pathways, Bionomics Limited, Boehringer Ingelheim, Otsuka Pharmaceutical Development & Commercialization, Inc., Halucenex Life Sciences, Bionorica SE, MAPS Europe B.V., Hoffmann-La Roche, Praxis Precision Medicines, Alto Neuroscience, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Psy Therapeutics Inc, Chronos Therapeutics, Mydecine Innovations Group, ATAI LIFE SCIENCES N.V., Acer Therapeutics, Alzamend Neuro, Inc., Innovation1 Biotech Inc., Lophora, Virpax Pharmaceuticals, Alto Neuroscience, VistaGen, ANANDA Scientific, Bright Minds Biosciences, and others.
· *Key Post-traumatic Stress Disorder Pipeline Therapies*: NYX-783, NBTX-001, JZP150, Psilocybin, BNC210, BI 1358894, Brexpiprazole, BX-1, MDMA, Balovaptan, PRAX-114, ALTO-100, Lu AG06466, TNX-102, PSY-05, TrkB Modulator, MYCO-001, EMP-01 / MDMA derivative, ACER-801, AL001, Psilocin Prodrug, PES200, ALTO-100, ALTO-202, Liquid Structure™ Cannabidiol (CBD), and others.
Dive deep into rich insights for drugs for post-traumatic stress disorder treatment, visit @*Post-traumatic Stress Disorder Treatment** *
*Table of Contents*
1. Post-traumatic Stress Disorder Pipeline Report Introduction
2. Post-traumatic Stress Disorder Pipeline Report Executive Summary
3. Post-traumatic Stress Disorder Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Post-traumatic Stress Disorder Pipeline Therapeutics
6. Post-traumatic Stress Disorder Pipeline: Late Stage Products (Pre-registration)
7. Post-traumatic Stress Disorder Pipeline: Late Stage Products (Phase III)
7.1 Brexpiprazole: Otsuka Pharmaceutical Development & Commercialization
8. Post-traumatic Stress Disorder Pipeline: Mid Stage Products (Phase II)
8.1 BNC 210: Bionomics
9. Post-traumatic Stress Disorder Pipeline: Early Stage Products (Phase I)
9.1 Lu AG06466: H. Lundbeck A/S
10. Post-traumatic Stress Disorder Pipeline Therapeutics Assessment
11. Inactive Products in the Post-traumatic Stress Disorder Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products in the Post-traumatic Stress Disorder Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
For further information on the post-traumatic stress disorder pipeline therapeutics, reach out @*Best Therapy for **Post-traumatic Stress Disorder*
*Related Reports*
*Post Traumatic Stress Disorder Epidemiology*
*Post Traumatic Stress Disorder Epidemiology Forecast **– 2032* report delivers an in-depth understanding of the disease, historical, and forecasted post-traumatic stress disorder epidemiology in the 7MM.
*Post-traumatic Stress Disorder Market*
*Post-traumatic Stress Disorder Market Insights, Epidemiology, and Market Forecast – 2032 *report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key post-traumatic stress disorder companies, including *Aptinyx, Jazz Pharmaceuticals, Bionomics Limited, *among others.
*Bipolar Depression Market*
*Bipolar Depression Market Insights, Epidemiology, and Market Forecast **– 2032 *report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key bipolar depression companies, including *Intra-Cellular Therapies, Sunovion Pharmaceuticals, COMPASS Pathways,* among others.
*Schizophrenia Market*
*Schizophrenia Market Insights, Epidemiology, and Market Forecast **– 2032 *report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key schizophrenia companies, including *Neurocrine Bioscience, Takeda Pharmaceutical Company, Memory Pharmaceuticals,* among others.
*Epilepsy Market*
*Epilepsy Market Insights, Epidemiology, and Market Forecast **– 2032 *report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key epilepsy companies, including *Eisai Co.LTD., Alexza Pharmaceuticals, Xenon Pharmaceuticals,* among others.
*Migraine Market*
*Migraine Market Insights, Epidemiology, and Market Forecast **– 2032 *report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key migraine companies, including *Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics,* among others.
*Other Trending Reports*
*Goitre Market** | **Thymus Cancer Market** | **US Healthcare Outlook Report** | **Venous Stenosis Market** | **Negative Pressure Wound Therapy Systems Market** | **Metrorrhagia Market** | **Dysfunctional Uterine Bleeding Market** | **Hypereosinophilic Syndrome Market** | **Age-related Vision Dysfunction Market** | **Dental Lasers Market** | **CRISPR Therapies Pipeline Insight** | **Cell And Gene Therapy For Multiple Myeloma Market** | **Drug Hypersensitivity Market** | **Dysthymia Market** | **Persistent Depressive Disorder Market** | **Cancer Vaccines Market** | **Weight Loss/Weight Management (Obesity) Market** | **Food Allergy Market** | **Obsessive-Compulsive Disorder Market** | **Tumor Ablation Market** | **Physiotherapy Equipment Market** | **CAR-T Pipeline Insight** | **Anti-Post-traumatic Stress Disorder Market** | **Radiofrequency Ablation Devices Market** | **Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market** | **Gastro Intestinal Bleeding Market** | **Trastuzumab Biosimilars Insight** | **Varicose Veins Market** | **Germ Cell Tumor Market** | **Intracardiac Echocardiography Devices Market** | **India Healthcare Outlook Report** | **Crows Feet Market Insight** | **Seborrhoeic Dermatitis Market** | **Injectable Drug Delivery Devices Market** | **Structural Heart Devices Market** | **Substance (Drug) Abuse Market*
*Related Healthcare Blogs*
*Telepyschiatry Market*
*Digital Therapeutics for Mental Health*
*PTSD Treatment Market** *
*About DelveInsight*
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.
*Connect with us at* *LinkedIn** *
CONTACT: Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com